HB002.1M / Zhejiang Huahai Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HB002.1M / Zhejiang Huahai Pharma
NCT03387566: A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration

Completed
1
21
RoW
HB002.1M, Recombinant Human Vascular Endothelial Growth Factor Receptor-Immunoglobulin(IgG) Fc Fusion Protein Ophthalmic Injection
Huabo Biopharm Co., Ltd.
Neovascular Age-Related Macular Degeneration
02/20
03/20

Download Options